Tomescu L, Cosma A, Pasca Fenesan M, Melnic E, Petrovici V, Sarb S
Curr Issues Mol Biol. 2024; 46(6):5161-5177.
PMID: 38920982
PMC: 11202497.
DOI: 10.3390/cimb46060310.
Tsantes A, Petrou E, Tsante K, Sokou R, Frantzeskaki F, Domouchtsidou A
Cancers (Basel). 2024; 16(11).
PMID: 38893201
PMC: 11171168.
DOI: 10.3390/cancers16112082.
Ibuki E, Kadota K, Kimura N, Ishikawa R, Oshima M, Okano K
Heliyon. 2024; 10(1):e23928.
PMID: 38205326
PMC: 10777074.
DOI: 10.1016/j.heliyon.2023.e23928.
Pavlovic D, Niciforovic D, Markovic M, Papic D
Clin Med Insights Oncol. 2023; 17:11795549231220297.
PMID: 38152726
PMC: 10752082.
DOI: 10.1177/11795549231220297.
Hisada Y, Mackman N
Res Pract Thromb Haemost. 2023; 7(3):100123.
PMID: 37122533
PMC: 10139954.
DOI: 10.1016/j.rpth.2023.100123.
Circulating biomarkers in malignant pleural mesothelioma.
Viscardi G, Di Natale D, Fasano M, Brambilla M, Lobefaro R, De Toma A
Explor Target Antitumor Ther. 2022; 1(6):434-451.
PMID: 36046389
PMC: 9400735.
DOI: 10.37349/etat.2020.00028.
Immunocytochemistry of effusion fluids: Introduction to SCIP approach.
Shidham V, Layfield L
Cytojournal. 2022; 19:3.
PMID: 35541032
PMC: 9079320.
DOI: 10.25259/CMAS_02_05_2021.
Immunocytochemistry of effusions: Processing and commonly used immunomarkers.
Shidham V, Janikowski B
Cytojournal. 2022; 19:6.
PMID: 35541029
PMC: 9079319.
DOI: 10.25259/CMAS_02_15_2021.
Targeting Podoplanin for the Treatment of Osteosarcoma.
Takemoto A, Takagi S, Ukaji T, Gyobu N, Kakino M, Takami M
Clin Cancer Res. 2022; 28(12):2633-2645.
PMID: 35381070
PMC: 9359727.
DOI: 10.1158/1078-0432.CCR-21-4509.
Introduction to the second edition of 'Diagnostic Cytopathology of Serous Fluids' as CytoJournal Monograph (CMAS) in Open Access.
Shidham V, Layfield L
Cytojournal. 2022; 18:30.
PMID: 35126608
PMC: 8813611.
DOI: 10.25259/CMAS_02_01_2021.
Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment.
Hwang B, Park S, Cho E, Zhang X, Lee S, Ahn H
Front Immunol. 2022; 12:807600.
PMID: 34987523
PMC: 8721674.
DOI: 10.3389/fimmu.2021.807600.
Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
Ukaji T, Takemoto A, Shibata H, Kakino M, Takagi S, Katayama R
Cancer Sci. 2021; 112(6):2299-2313.
PMID: 33735501
PMC: 8177788.
DOI: 10.1111/cas.14891.
Podoplanin as an Attractive Target of CAR T Cell Therapy.
Waseda M, Kaneko S
Cells. 2020; 9(9).
PMID: 32858947
PMC: 7564405.
DOI: 10.3390/cells9091971.
Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the "Universal" CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2.
Kuwata T, Yoneda K, Mori M, Kanayama M, Kuroda K, Kaneko M
Cells. 2020; 9(4).
PMID: 32260559
PMC: 7226802.
DOI: 10.3390/cells9040888.
Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.
Kato Y, Ito Y, Ohishi T, Kawada M, Nakamura T, Sayama Y
Monoclon Antib Immunodiagn Immunother. 2020; 39(2):37-44.
PMID: 32182186
PMC: 7185362.
DOI: 10.1089/mab.2020.0001.
Epitope Analysis of an Anti-Whale Podoplanin Monoclonal Antibody, PMab-237, Using Flow Cytometry.
Sayama Y, Sano M, Kaneko M, Kato Y
Monoclon Antib Immunodiagn Immunother. 2020; 39(1):17-22.
PMID: 31934820
PMC: 7044787.
DOI: 10.1089/mab.2019.0045.
Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
Xu M, Wang X, Pan Y, Zhao X, Yan B, Ruan C
BMC Cancer. 2019; 19(1):599.
PMID: 31208371
PMC: 6580467.
DOI: 10.1186/s12885-019-5808-9.
Establishment of a monoclonal antibody PMab-225 against alpaca podoplanin for immunohistochemical analyses.
Kato Y, Furusawa Y, Yamada S, Itai S, Takei J, Sano M
Biochem Biophys Rep. 2019; 18:100633.
PMID: 30997422
PMC: 6451175.
DOI: 10.1016/j.bbrep.2019.100633.
Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin.
Furusawa Y, Yamada S, Itai S, Nakamura T, Takei J, Sano M
Biochem Biophys Rep. 2019; 18:100631.
PMID: 30984883
PMC: 6446048.
DOI: 10.1016/j.bbrep.2019.100631.
Therapeutic efficacy evaluation of radioimmunotherapy with Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.
Sudo H, Tsuji A, Sugyo A, Saga T, Kaneko M, Kato Y
Cancer Sci. 2019; 110(5):1653-1664.
PMID: 30801908
PMC: 6500970.
DOI: 10.1111/cas.13979.